Stephen Cunningham

Direttore/Membro del Consiglio presso Engrail Therapeutics, Inc.

Health Technology

Profilo

Stephen Cunningham is currently the Director & Chief Development Officer at Engrail Therapeutics, Inc. He previously worked as a Director at Chase Pharmaceuticals Corp.

Posizioni attive di Stephen Cunningham

Società	Posizione	Inizio
Engrail Therapeutics, Inc. Engrail Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engrail Therapeutics, Inc. acquires, develops and commercialize transformative medicines. The company was founded in 2019 and is headquartered in San Diego, CA.	Direttore/Membro del Consiglio	-

Tutte le posizioni attive di Stephen Cunningham

Precedenti posizioni note di Stephen Cunningham

Società	Posizione	Fine
Chase Pharmaceuticals Corp. Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Stephen Cunningham

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Stephen Cunningham

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Chase Pharmaceuticals Corp. Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC.	Health Technology
Engrail Therapeutics, Inc. Engrail Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engrail Therapeutics, Inc. acquires, develops and commercialize transformative medicines. The company was founded in 2019 and is headquartered in San Diego, CA.	Health Technology